KCNK3 and pulmonary arterial hypertension: Guanylate cyclase activators, endothelin receptor antagonists and prostacyclin analogues are established vascular therapeutic strategies in the treatment of PAH, acting to reduce vasoconstriction and smooth muscle proliferation, and all three will stimulate activation of TASK‐1 channels in PASMCs, which would contribute to their therapeutic benefit.